Anders Widmark
Overview
Explore the profile of Anders Widmark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2848
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grefve J, Soderkvist K, Gunnlaugsson A, Sandgren K, Jonsson J, Keeratijarut Lindberg A, et al.
Phys Imaging Radiat Oncol
. 2024 Sep;
31:100633.
PMID: 39286772
Background And Purpose: Dose escalation in external radiotherapy of prostate cancer shows promising results in terms of biochemical disease-free survival. Boost volume delineation guidelines are sparse which may cause high...
2.
Zarei M, Wallsten E, Grefve J, Soderkvist K, Gunnlaugsson A, Sandgren K, et al.
Acta Oncol
. 2024 Jun;
63:503-510.
PMID: 38912830
Background: The delineation of intraprostatic lesions is vital for correct delivery of focal radiotherapy boost in patients with prostate cancer (PC). Errors in the delineation could translate into reduced tumour...
3.
Nilsson E, Sandgren K, Grefve J, Jonsson J, Axelsson J, Keeratijarut Lindberg A, et al.
Commun Med (Lond)
. 2023 Nov;
3(1):164.
PMID: 37945817
Background: Multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) are widely used for the management of prostate cancer (PCa). However, how these modalities complement each other in PCa...
4.
Sandgren K, Strandberg S, Jonsson J, Grefve J, Keeratijarut Lindberg A, Nilsson E, et al.
Nucl Med Commun
. 2023 Aug;
44(11):997-1004.
PMID: 37615497
Objective: PET/CT and multiparametric MRI (mpMRI) are important diagnostic tools in clinically significant prostate cancer (csPC). The aim of this study was to compare csPC detection rates with [ 68...
5.
Jaremo H, Semenas J, Bergstrom S, Lundholm M, Thysell E, Widmark A, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173903
MicroRNAs (miRNAs) are aberrantly expressed in prostate cancer (PC), but comprehensive knowledge about their levels and function in metastatic PC is lacking. Here, we explored the differential expression of miRNA...
6.
Josefsson A, Jellvert A, Holmberg E, Brasso K, Petersen P, Aaltomaa S, et al.
Acta Oncol
. 2023 Apr;
62(4):372-380.
PMID: 37073813
Background: Historically, endocrine therapy was used in a range of scenarios in patients with rising PSA, both as a treatment for locally advanced non-metastatic prostate cancer and PSA recurrence following...
7.
Bjoreland U, Notstam K, Fransson P, Soderkvist K, Beckman L, Jonsson J, et al.
Radiat Oncol
. 2023 Jan;
18(1):1.
PMID: 36593460
Background: Perirectal spacers may be beneficial to reduce rectal side effects from radiotherapy (RT). Here, we present the impact of a hyaluronic acid (HA) perirectal spacer on rectal dose as...
8.
Wikstrom P, Bergstrom S, Josefsson A, Semenas J, Nordstrand A, Thysell E, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358614
Prostate cancer (PC) bone metastases can be divided into transcriptomic subtypes, by us termed MetA-C. The MetB subtype, constituting about 20% of the cases, is characterized by high cell cycle...
9.
Almen A, Gudjonsdottir J, Heimland N, Hojgaard B, Waltenburg H, Widmark A
Br J Radiol
. 2021 Dec;
95(1130):20210700.
PMID: 34898256
Objective: The purpose of this study was to explore the feasibility to determine regional diagnostic reference levels (RDRLs) for paediatric conventional and CT examinations using the European guidelines and to...
10.
Thysell E, Kohn L, Semenas J, Jaremo H, Freyhult E, Lundholm M, et al.
Mol Oncol
. 2021 Dec;
16(4):846-859.
PMID: 34889043
To improve treatment of metastatic prostate cancer, the biology of metastases needs to be understood. We recently described three subtypes of prostate cancer bone metastases (MetA-C), based on differential gene...